In the HNF4α-negative HCC cell line treated with tazemetostat, we observed a marked upregulation of HNF4a, BHMT, and CDO1, suggesting that EZH2 exerts a suppressive effect on HNF4α expression. Here, EZH2 is linked to hepatocellular carcinoma.